Sparfloxacin: Potential clinical and economic impact in the treatment of respiratory infections

Author(s): Stein GE, Havlichek DH


Sparfloxacin is a new oral fluoroquinolone antimicrobial that is highly active against common respiratory pathogens, including multiresistant strains. It is well absorbed and has excellent penetration into upper and lower respiratory tissues. Sparfloxacin is administered once a day and does not interfere with the metabolism of other drugs. The agent is highly effective and safe in the treatment of acute sinusitis, exacerbations of chronic bronchitis, and community-acquired pneumonia. Due to its activity against multidrug-resistant respiratory pathogens, it has the potential to prevent hospitalization as well as decrease parenteral antibiotic therapy. Consequently, it may generate significant pharmacoeconomic benefits to patients and payers of medical care.

Similar Articles

The discovery of aspirin's antithrombotic effects

Author(s): Miner J, Hoffhines A

Salicylate, A new plant hormone

Author(s): Raskin I

Pharmacokinetics and inflammatory fluid penetration of sparfloxacin

Author(s): Johnson JH, Cooper MA, Andrews JM, Wise R

In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent

Author(s): Cooper MA, Andrews JM, Ashby JP, Matthews RS, Wise R

Development of forced degradation and stability indicating studies of drugs-A review

Author(s): Blessy M, Patel RD, Prajapati PN, Agrawal YK